Hidden layers of regulation that control the activity of genes can produce drug-resistant, surviving cells. New research helps explain how therapy-resistant cancers arise — findings with important implications for the future of cancer therapy.
Oncology is the most advanced area in genomics right now. The field is setting the standard for other indications to follow and improve upon.
GlaxoSmithKline Chief Executive, Emma Wamsley is keeping her promise to cut the drugmaker’s pharmaceutical portfolio — the company said today that it is handing its rare disease gene therapy drugs to Orchard Therapeutics.
A new cancer cell-based assay could help doctors diagnose cancer, better monitor the disease, and take a step closer to customised treatment for individual patients.
A literature review finds an increased risk of cancer, late-stage cancer, and mortality, with increased waiting time between a positive screening and start of diagnostic testing.
Use of one of a cancer treatment offered on the basis of biomarkers instead of tissue type is being restricted because of inaccurate, insensitive diagnostic tests.
Material left out of common processes for sequencing genetic material in cancer tumours may actually carry important information about why only some people respond to immunotherapy.
Scientists have developed a straightforward, computational way to measure cellular age, a feat that may lead to better, simpler screening and monitoring methods for cancer and other diseases.
Researchers have identified nearly 200 mutations in non-coding DNA that play a role in cancer. Each mutation could represent a new cancer drug target.
Singlera Genomics, a non-invasive genetic diagnostics company that focuses on early-stage cancer detection, has secured a $60 million Series A+ financing.
Combining a cancer therapy with a second drug therapy that helps suppress tumour blood vessels found in cancer cells can help to significantly reduce the spread of breast cancer tumours while also causing cancer cell death.